EXTENDED - TODAY ONLY: MarketBeat All Access For Just $399 $199 (save 50%)
Special Offer: Just $199
×
S&P 500   3,957.63 (-0.16%)
DOW   33,852.53 (+0.01%)
QQQ   280.57 (-0.76%)
AAPL   141.17 (-2.11%)
MSFT   240.33 (-0.59%)
META   109.46 (+0.63%)
GOOGL   95.19 (-0.90%)
AMZN   92.42 (-1.63%)
TSLA   180.83 (-1.14%)
NVDA   156.39 (-1.19%)
NIO   10.50 (+3.75%)
BABA   79.86 (+5.25%)
AMD   73.39 (+0.27%)
T   19.01 (+1.01%)
MU   55.12 (-1.13%)
CGC   3.42 (+0.59%)
F   13.75 (+0.15%)
GE   85.66 (+0.22%)
DIS   94.69 (-1.05%)
AMC   7.43 (+1.36%)
PYPL   77.64 (-2.87%)
PFE   49.49 (-0.16%)
NFLX   280.96 (-0.07%)
S&P 500   3,957.63 (-0.16%)
DOW   33,852.53 (+0.01%)
QQQ   280.57 (-0.76%)
AAPL   141.17 (-2.11%)
MSFT   240.33 (-0.59%)
META   109.46 (+0.63%)
GOOGL   95.19 (-0.90%)
AMZN   92.42 (-1.63%)
TSLA   180.83 (-1.14%)
NVDA   156.39 (-1.19%)
NIO   10.50 (+3.75%)
BABA   79.86 (+5.25%)
AMD   73.39 (+0.27%)
T   19.01 (+1.01%)
MU   55.12 (-1.13%)
CGC   3.42 (+0.59%)
F   13.75 (+0.15%)
GE   85.66 (+0.22%)
DIS   94.69 (-1.05%)
AMC   7.43 (+1.36%)
PYPL   77.64 (-2.87%)
PFE   49.49 (-0.16%)
NFLX   280.96 (-0.07%)
S&P 500   3,957.63 (-0.16%)
DOW   33,852.53 (+0.01%)
QQQ   280.57 (-0.76%)
AAPL   141.17 (-2.11%)
MSFT   240.33 (-0.59%)
META   109.46 (+0.63%)
GOOGL   95.19 (-0.90%)
AMZN   92.42 (-1.63%)
TSLA   180.83 (-1.14%)
NVDA   156.39 (-1.19%)
NIO   10.50 (+3.75%)
BABA   79.86 (+5.25%)
AMD   73.39 (+0.27%)
T   19.01 (+1.01%)
MU   55.12 (-1.13%)
CGC   3.42 (+0.59%)
F   13.75 (+0.15%)
GE   85.66 (+0.22%)
DIS   94.69 (-1.05%)
AMC   7.43 (+1.36%)
PYPL   77.64 (-2.87%)
PFE   49.49 (-0.16%)
NFLX   280.96 (-0.07%)
S&P 500   3,957.63 (-0.16%)
DOW   33,852.53 (+0.01%)
QQQ   280.57 (-0.76%)
AAPL   141.17 (-2.11%)
MSFT   240.33 (-0.59%)
META   109.46 (+0.63%)
GOOGL   95.19 (-0.90%)
AMZN   92.42 (-1.63%)
TSLA   180.83 (-1.14%)
NVDA   156.39 (-1.19%)
NIO   10.50 (+3.75%)
BABA   79.86 (+5.25%)
AMD   73.39 (+0.27%)
T   19.01 (+1.01%)
MU   55.12 (-1.13%)
CGC   3.42 (+0.59%)
F   13.75 (+0.15%)
GE   85.66 (+0.22%)
DIS   94.69 (-1.05%)
AMC   7.43 (+1.36%)
PYPL   77.64 (-2.87%)
PFE   49.49 (-0.16%)
NFLX   280.96 (-0.07%)
NASDAQ:XENT

Intersect ENT - XENT Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Add
Compare
Today's Range
$28.24
▼
$28.24
50-Day Range
$28.24
▼
$28.24
52-Week Range
$15.92
▼
$28.25
Volume
14,512 shs
Average Volume
351,526 shs
Market Capitalization
$954.91 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
XENT stock logo

About Intersect ENT (NASDAQ:XENT) Stock

Intersect ENT, Inc. operates as an ear, nose, and throat (ENT) medical technology company in the United States. The company offers PROPEL, a steroid releasing implant to open the surgically enlarged sinus; PROPEL Mini, a releasing implant to treat patients undergoing frontal sinus surgery; and PROPEL Contour, a steroid releasing implant for the treatment of frontal and maxillary sinus ostia, or openings, of the dependent sinuses. It also provides SINUVA, a steroid releasing implant for the treatment of patients in the physician office setting; VENSURE Navigable and Stand-alone balloon, a sterile and single-use device, used to access and treat frontal, sphenoid sinus, and maxillary ostia in adults using a trans-nasal approach; and CUBE Navigation System, a virtual guidance platform for high precision ENT and ENT related skull-base surgeries. The company was formerly known as Sinexus, Inc. and changed its name to Intersect ENT, Inc. in November 2009. Intersect ENT, Inc. was incorporated in 2003 and is headquartered in Menlo Park, California.

Receive XENT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Intersect ENT and its competitors with MarketBeat's FREE daily newsletter.

XENT Stock News Headlines

July 15, 2022 | benzinga.com
Nalu Medical, Inc. Names Thomas West President...
July 14, 2022 | finance.yahoo.com
Nalu Medical, Inc. Names Thomas West President and Chief Executive Officer
May 12, 2022 | finance.yahoo.com
Medtronic will sell Intersect ENT subsidiary Fiagon to Hemostasis to win FTC approval of acquisition
April 28, 2022 | finance.yahoo.com
DexCom (DXCM) Misses Q1 Earnings Estimates
April 20, 2022 | finance.yahoo.com
Those who invested in Intersect ENT (NASDAQ:XENT) five years ago are up 55%
February 24, 2022 | finance.yahoo.com
Teleflex (TFX) Q4 Earnings and Revenues Surpass Estimates
February 17, 2022 | seekingalpha.com
Medtronic, Intersect ENT said to finalize divestiture plans to help with antitrust concerns
January 25, 2022 | nasdaq.com
Intersect ENT: Real-world Data Support Use Of PROPEL In Patients Undergoing Endoscopic Sinus Surgery
January 25, 2022 | finance.yahoo.com
Real-World Evidence Study Demonstrates Intersect ENT’s PROPEL® Sinus Implant Reduces Healthcare Resource Utilization
December 2, 2021 | finance.yahoo.com
Why Is Intersect ENT (XENT) Down 0.6% Since Last Earnings Report?
November 30, 2021 | nasdaq.com
Is Intersect ENT (NASDAQ:XENT) Using Too Much Debt?
November 18, 2021 | finance.yahoo.com
Intersect ENT's (XENT) Sell-Off on Track Amid COVID Woes
November 3, 2021 | finance.yahoo.com
Intersect ENT (XENT) Q3 Loss Widens, Sell-Off Process On Track
November 2, 2021 | finance.yahoo.com
Intersect ENT Reports Third Quarter 2021 Financial Results
October 28, 2021 | finance.yahoo.com
First Implants of PROPEL® Contour in Patients with Chronic Rhinosinusitis Following Frontal Sinus Surgery in Europe
October 22, 2021 | finance.yahoo.com
How Many Intersect ENT, Inc. (NASDAQ:XENT) Shares Do Institutions Own?
September 22, 2021 | finance.yahoo.com
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates XENT, INOV, HOMB, IDEX; Shareholders are Encouraged to Contact the Firm
September 14, 2021 | finance.yahoo.com
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates SBKK, SAFM, LMRK, XENT; Shareholders are Encouraged to Contact the Firm
September 14, 2021 | finance.yahoo.com
Lifshitz Law Firm, P.C. Announces Investigation of DVCR, INOV, XENT, LMRK
September 13, 2021 | finance.yahoo.com
SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Intersect ENT, Inc. - XENT
September 4, 2021 | finance.yahoo.com
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates INOV, GTS, XONE, XENT; Shareholders are Encouraged to Contact the Firm
September 4, 2021 | finance.yahoo.com
Lifshitz Law Firm, P.C. Announces Investigation of INOV, XENT, LMRK, and GTS
August 30, 2021 | finance.yahoo.com
Lifshitz Law Firm, P.C. Announces Investigation of XENT, LMRK, TGRF, and TRIL
August 27, 2021 | finance.yahoo.com
SHAREHOLDER ALERT: WeissLaw LLP Reminds XENT, STRF, IEC, and RYFL Shareholders About Its Ongoing Investigations
August 23, 2021 | finance.yahoo.com
Intersect ENT's (XENT) Sell Off Plan Strategic Amid Pandemic
See More Headlines

Receive XENT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Intersect ENT and its competitors with MarketBeat's FREE daily newsletter.

XENT Company Calendar

Last Earnings
11/02/2021
Today
11/29/2022
Fiscal Year End
12/31/2022
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Surgical & Medical Instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:XENT
CUSIP
N/A
CIK
1271214
Web
www.intersectent.com
Phone
(650) 641-2100
Fax
866-736-1251
Employees
433
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
($4.79)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-159,630,000.00
Net Margins
-161.94%
Pretax Margin
-163.16%
Return on Equity
-709.52%
Return on Assets
-48.18%

Debt

Debt-to-Equity Ratio
6.89
Current Ratio
1.88
Quick Ratio
1.50

Sales & Book Value

Annual Sales
$106.75 million
Price / Sales
8.95
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($2.06) per share
Price / Book
-13.71

Miscellaneous

Outstanding Shares
33,814,000
Free Float
33,104,000
Market Cap
$954.91 million
Optionable
Optionable
Beta
1.45

Key Executives

  • Mr. Thomas A. West (Age 58)
    Pres, CEO & Director
    Comp: $908.97k
  • Mr. Richard A. Meier (Age 62)
    Exec. VP & CFO
    Comp: $621.76k
  • Mr. Patrick A. Broderick (Age 63)
    Exec. VP, Gen. Counsel & Corp. Sec.
    Comp: $138.46k
  • Ms. Reyna M. Fernandez
    Chief Human Resource Officer
  • Mr. Drake R. Parker (Age 58)
    Advisor of Strategic Initiatives

Key Competitors

View All Competitors













XENT Stock - Frequently Asked Questions

How were Intersect ENT's earnings last quarter?

Intersect ENT, Inc. (NASDAQ:XENT) posted its quarterly earnings results on Tuesday, November, 2nd. The medical equipment provider reported ($0.48) earnings per share for the quarter, missing the consensus estimate of ($0.42) by $0.06. The medical equipment provider earned $24.40 million during the quarter, compared to analysts' expectations of $29.63 million. Intersect ENT had a negative trailing twelve-month return on equity of 709.52% and a negative net margin of 161.94%.

What is Thomas West's approval rating as Intersect ENT's CEO?

7 employees have rated Intersect ENT Chief Executive Officer Thomas West on Glassdoor.com. Thomas West has an approval rating of 41% among the company's employees. This puts Thomas West in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Intersect ENT own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Intersect ENT investors own include SEASPAN CORP/SH SH (SSW), Textainer Group (TGH), iShares MSCI Brazil ETF (EWZ), Costamare (CMRE), Mimecast (MIME), EOG Resources (EOG), Air Transport Services Group (ATSG), BioCryst Pharmaceuticals (BCRX), Gilead Sciences (GILD) and AbbVie (ABBV).

What is Intersect ENT's stock symbol?

Intersect ENT trades on the NASDAQ under the ticker symbol "XENT."

What is Intersect ENT's stock price today?

One share of XENT stock can currently be purchased for approximately $28.24.

How much money does Intersect ENT make?

Intersect ENT (NASDAQ:XENT) has a market capitalization of $954.91 million and generates $106.75 million in revenue each year. The medical equipment provider earns $-159,630,000.00 in net income (profit) each year or ($4.79) on an earnings per share basis.

How many employees does Intersect ENT have?

The company employs 433 workers across the globe.

How can I contact Intersect ENT?

Intersect ENT's mailing address is 1555 ADAMS DRIVE, MENLO PARK CA, 94025. The official website for the company is www.intersectent.com. The medical equipment provider can be reached via phone at (650) 641-2100, via email at ir@intersectent.com, or via fax at 866-736-1251.

This page (NASDAQ:XENT) was last updated on 11/29/2022 by MarketBeat.com Staff